Announcements Trials
Browse Landscape

Phase

Phase 3 3

Status

Active not recruiting 2Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Colorectal Neoplasms 3Uterine Cervical Neoplasms 1Rectal Neoplasms 1Rectal Diseases 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neoplasms 1Intestinal Neoplasms 1Intestinal Diseases 1Gastrointestinal Neoplasms 1Gastrointestinal Diseases 1Esophageal Neoplasms 1Digestive System Neoplasms 1Digestive System Diseases 1Colonic Neoplasms 1Colonic Diseases 1

Interventions

Cetuximab 5Bevacizumab 4pembrolizumab 3Leucovorin 3Irinotecan 3Fluorouracil 3trifluridine tipiracil drug combination 2trastuzumab deruxtecan 2larotrectinib 2encorafenib 2binimetinib 2Trastuzumab 2Oxaliplatin 2Nivolumab 2HMPL-013 2Afatinib 2ulixertinib 1tucatinib 1trastuzumab biosimilar HLX02 1trametinib 1sotorasib 1sapanisertib 1relatlimab 1regorafenib 1pralsetinib 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1ipatasertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has announcements × Colorectal Neoplasms × Irinotecan × Clear all
NCT04008030 2025-10-03

CheckMate 8HW

Bristol-Myers Squibb

Phase 3 Active not recruiting
839 enrolled 22 charts 1 FDA
Gastrointestinal

Colorectal Neoplasms

NCT04607421 2025-08-14

A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

Pfizer

Phase 3 Active not recruiting
831 enrolled 2 FDA
Gastrointestinal

Colonic Diseases, Colonic Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Neoplasms, Rectal Diseases, Rectal Neoplasms, Colorectal Neoplasms

NCT02928224 2023-12-21

BEACON CRC

Pfizer

Phase 3 Completed
702 enrolled 82 charts 1 FDA
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡